Goldman Sachs Group Inc. Has $40.35 Million Stake in Catalent, Inc. (NYSE:CTLT)

Goldman Sachs Group Inc. decreased its holdings in Catalent, Inc. (NYSE:CTLT) by 57.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 897,944 shares of the company’s stock after selling 1,220,091 shares during the quarter. Goldman Sachs Group Inc. owned 0.50% of Catalent worth $40,345,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of CTLT. Gladius Capital Management LP acquired a new stake in Catalent in the 3rd quarter worth about $28,000. GAMMA Investing LLC bought a new position in Catalent in the 4th quarter valued at about $33,000. Cary Street Partners Investment Advisory LLC increased its holdings in Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after buying an additional 709 shares during the period. Rakuten Securities Inc. bought a new position in Catalent in the 4th quarter valued at about $46,000. Finally, Federated Hermes Inc. bought a new position in Catalent in the 4th quarter valued at about $46,000.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Stephens reissued an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. StockNews.com assumed coverage on shares of Catalent in a report on Friday, June 14th. They issued a “sell” rating on the stock. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $54.05.

Insider Buying and Selling

In related news, insider Ricky Hopson sold 1,401 shares of Catalent stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the sale, the insider now directly owns 20,617 shares in the company, valued at approximately $1,118,678.42. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.31% of the stock is owned by corporate insiders.

Catalent Stock Down 0.4 %

NYSE:CTLT opened at $54.84 on Friday. The firm’s 50 day simple moving average is $55.51 and its 200 day simple moving average is $52.99. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. Catalent, Inc. has a one year low of $31.80 and a one year high of $60.20. The company has a market cap of $9.92 billion, a PE ratio of -8.99, a P/E/G ratio of 6.62 and a beta of 1.20.

Catalent (NYSE:CTLT) last posted its earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.11 billion. On average, research analysts anticipate that Catalent, Inc. will post 0.28 earnings per share for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.